-
Atazanavir (Reyetaz®), an azapeptide class of protease inhibitors, was approved by the US FDA for use in HIV infection on June 20, 2003. Atazanavir (ATV) has a unique pharmacokinetic profile allowing for once-daily dosing, which is optimized when taken with food.
-
-
-
The following summary of selected abstracts from 3 meetings will be published in multiple parts. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) met in Chicago September 14-17, 2003. The Infectious Disease Society of America (IDSA) met in San Diego October 9-12, 2003. The American Society of Tropical Medicine and Hygiene meets in Philadelphia December 3-7, 2003.
-
Genetically engineered B lymphocytes were used for rapid detection and identification of pathogens, a methodology with potential use in diagnostics, biowarfare defense, and biomonitoring of food and water.
-
Compliance with a protocol for managing catheter-related bacteremia was improved from 56% to 75% simply by sending a reminder by e-mail.
-
An outbreak of Pseudomonas surgical-site infections was traced to the infected thumbnail of a cardiac surgeon. The outbreak stopped after the infected nail was removed.
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction. The drug is a selective aldosterone blocker, a new class of drug for the treatment of CHF.
-
The objective of this monograph is to provide an overview of the scope of allergic disorders, and review the current understanding of the mechanism of the allergic response. Due to the extensive nature of the topic, we will limit our discussion to systemic reactions eliciting an IgE-mediated response. Further, the intimate relationship between organs involved will be reviewed, particularly the relationship between allergic rhinitis and asthma. Part I includes the current evaluation, including historical features, exposures, physical exam findings, and ancillary diagnostic options will be reviewed.
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
